Thyroid Cancer Treatment Options
Thyroid cancer treatment usually starts with surgery, and the rest of the plan depends on the exact type and stage of the cancer. This overview walks through the standard treatment options for thyroid cancer — surgery, radioactive iodine therapy, thyroid hormone therapy, targeted drugs, and chemotherapy — and where newer approaches currently stand, checked against current National Cancer Institute treatment guidance.
Key Takeaways
- Surgery, usually a total thyroidectomy or lobectomy, is the main treatment for most thyroid cancers; the choice depends mainly on tumor size and recurrence risk.
- Radioactive iodine (RAI) therapy is often given after surgery for differentiated thyroid cancers to destroy remaining thyroid tissue, and it appears most useful for patients at intermediate or high risk of recurrence.
- Thyroid hormone therapy is also a standard treatment after thyroidectomy — beyond replacing the hormone the gland made, it is often dosed to suppress TSH, since this may help slow tumor growth in higher-risk patients.
- Targeted drug therapy is used for advanced or recurrent thyroid cancer that no longer responds to surgery or RAI, with different drugs used for radioactive-iodine-refractory, medullary, and BRAF-mutated anaplastic disease.
- Chemotherapy is uncommon for differentiated thyroid cancers but may be used, often with radiation, for aggressive forms such as anaplastic thyroid cancer or metastatic medullary thyroid cancer.
Understanding Thyroid Cancer Treatment Options
When facing a diagnosis of thyroid cancer, patients are presented with a range of thyroid cancer treatment options tailored to their specific condition. The choice of treatment depends on several factors, including the type of thyroid cancer — differentiated types such as papillary and follicular carcinoma, or the less common medullary and anaplastic thyroid cancers — along with the stage of the disease and the patient’s age and general health. A team of specialists, which may include an endocrinologist, a surgeon experienced in thyroid disease, and an oncologist, typically works together on the treatment plan.
Differentiated thyroid cancers, which make up most cases, generally respond well to treatment when found early; how the outlook varies by cancer type and stage is a topic covered separately from treatment planning itself. The primary goal of thyroid cancer treatment is to remove or destroy cancer cells while limiting side effects and preserving quality of life.
Surgical Approaches for Thyroid Cancer
For nearly all patients with a primary tumor, an operation to remove some or all of the thyroid remains the first and most widely used treatment for thyroid cancer. How much of the gland comes out — a lobectomy versus a total or near-total thyroidectomy — is guided mainly by the patient’s age and by the size, number, and behavior of the tumor, along with whether cancer is found in nearby lymph nodes.
Total Thyroidectomy
A total thyroidectomy removes the entire thyroid gland, along with any affected lymph nodes found nearby. It is commonly used for larger tumors and when cancer is found in more than one part of the thyroid, in part because it makes follow-up monitoring with iodine scanning and blood tests more reliable. In an analysis of a large U.S. cancer registry, patients with papillary thyroid cancer tumors of 1 cm or larger who had a total thyroidectomy had a lower rate of recurrence than those who had a lobectomy; for tumors under 1 cm, whether a patient had a lobectomy or a total thyroidectomy made no measurable difference to recurrence. After a total thyroidectomy, patients need lifelong thyroid hormone replacement, and many are also given a higher, TSH-suppressive dose meant to lower the chance the cancer will come back; how much suppression is used depends on the person’s individual recurrence risk and other health conditions, since this approach has been linked to better progression-free outcomes but not clearly to longer overall survival. As with any thyroid surgery, potential risks include effects on the nearby parathyroid glands, which can lower blood calcium, and, less often, injury to the nerve controlling the vocal cords, which can cause hoarseness.
Lobectomy and Lymph Node Dissection
A lobectomy, or hemithyroidectomy, removes only the lobe of the thyroid that contains the cancer. This option may be appropriate for small (under 1 cm), low-risk, single-site papillary cancers confined to the thyroid, without a history of head or neck radiation or known lymph node involvement. Lobectomy is associated with fewer surgical complications than total thyroidectomy, though according to the National Cancer Institute, an estimated 5% to 10% of patients who have a lobectomy for this kind of low-risk cancer will later see the cancer return in the remaining thyroid tissue. Patients who have a lobectomy may not need lifelong thyroid hormone replacement if the remaining lobe still makes enough hormone. When cancer has spread, or is suspected to have spread, to nearby lymph nodes, those nodes are also removed and examined, which helps confirm the stage of the cancer.
Radioactive Iodine (RAI) Therapy
Radioactive iodine (RAI) therapy is a form of internal radiation therapy often used after surgery, particularly for differentiated thyroid cancers (papillary and follicular). It works by destroying thyroid tissue — including microscopic cancer cells — that remains after surgery, since only thyroid tissue readily absorbs iodine.
Purpose and Procedure of RAI
The radioactive form of iodine (iodine-131) is given by mouth, usually as a capsule or liquid, and a small test dose is typically given first to check whether the remaining tissue takes up iodine. Once absorbed, the radioactivity damages thyroid cells — cancerous and normal alike — while largely sparing tissue elsewhere in the body. RAI appears to lower the chance of recurrence for patients at intermediate or high risk of the cancer coming back; for many patients with low-risk, early-stage disease, research has not clearly shown that adding RAI improves long-term outcomes over surgery alone, so its use is weighed individually with the care team.
Post-Treatment Considerations
After RAI, patients follow radiation safety instructions from their care team to limit others’ radiation exposure for a short time. Short-term effects can include neck discomfort and changes in taste or dry mouth from effects on the salivary glands. In some patients, these salivary gland effects — and, less commonly, effects on the tear glands — can persist longer term, and RAI has also been linked to a small increased risk of a second cancer later in life; both are factors a care team weighs when recommending RAI. Ongoing follow-up with blood tests and imaging after RAI helps monitor thyroid hormone levels and check for signs that the cancer has returned.
Targeted Therapies and Chemotherapy
For patients with advanced or recurrent thyroid cancer that does not respond to surgery or radioactive iodine, targeted drug therapy and, in some situations, chemotherapy are additional treatment options.
Targeted Drug Therapies
Targeted drug therapy is an established option for certain advanced thyroid cancers, typically given as a pill that blocks specific proteins tumor cells need to grow. Sorafenib and lenvatinib, both in the tyrosine-kinase-inhibitor drug class, are options once differentiated thyroid cancer stops responding to radioactive iodine; vandetanib, cabozantinib, and selpercatinib are used instead when medullary thyroid cancer has spread beyond the neck. For anaplastic thyroid cancer, dabrafenib combined with trametinib is used specifically in patients whose tumor carries a particular mutation in the BRAF gene, identified through molecular testing of the tumor. These drugs are generally reserved for cancer that is advanced, recurrent, or no longer responding to standard treatment, rather than used as an initial therapy.
Role of Chemotherapy
Chemotherapy is generally not the main treatment for differentiated thyroid cancers (papillary and follicular), which often respond poorly to traditional chemotherapy drugs. It plays a larger role for less common, more aggressive forms: it may be used, sometimes together with radiation therapy, to help control anaplastic thyroid cancer, and it may be used to relieve symptoms in medullary thyroid cancer that has spread beyond the neck. In these situations, the goal is usually to shrink the tumor, ease symptoms, and support quality of life, and chemotherapy tends to bring a broader range of side effects than targeted therapy.
Latest Advances in Thyroid Cancer Treatment
Research into thyroid cancer treatment continues, particularly for cancers that no longer respond to the standard options above. Immunotherapy, which uses the body’s immune system to fight cancer, is being studied for thyroid cancer in clinical trials, but it is not yet an established, standard treatment. Molecular testing of tumors is also playing a growing role in matching patients to the targeted therapies described above, especially for cancers with BRAF or RET gene changes. Patients whose thyroid cancer has stopped responding to surgery, radioactive iodine, or approved targeted drugs may want to ask their care team about clinical trials, which continue to evaluate new drugs and treatment combinations.
Frequently Asked Questions
What is the primary treatment for most thyroid cancers?
For most thyroid cancers, especially differentiated types like papillary and follicular carcinoma, surgery — a lobectomy or total thyroidectomy — is the main treatment, often followed by radioactive iodine therapy to destroy any remaining cancer cells. The extent of surgery depends on tumor size, type, and whether it has spread to nearby lymph nodes.
When is radioactive iodine (RAI) therapy used for thyroid cancer?
RAI therapy is typically used after surgery for differentiated thyroid cancers to destroy any thyroid tissue or microscopic cancer cells that remain. It appears most beneficial for patients at intermediate or high risk of recurrence; for many patients with low-risk disease, evidence that it improves long-term outcomes is less clear.
Are there new treatment options for advanced thyroid cancer?
Yes. Tyrosine kinase inhibitors, and — for BRAF-mutated anaplastic thyroid cancer — targeted protein kinase inhibitors, are established options for disease that no longer responds to surgery or radioactive iodine. Immunotherapy is being tested in clinical trials for thyroid cancer but is not yet a standard treatment; patients with advanced disease can ask their care team about trial eligibility.
Sources
